SAN FRANCISCO, March 13, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE ...
ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in patients with chronic hepatitis delta SAN FRANCISCO, August 06, 2025--(BUSINESS WIRE)--Vir Biotechnology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback